Publications by authors named "Paul Wolfson"
Salivary epigenetic biomarkers may detect esophageal cancer. A total of 256 saliva samples from esophageal adenocarcinoma patients and matched volunteers were analyzed with Illumina EPIC methylation arrays. Three datasets were created, using 64% for discovery, 16% for testing and 20% for validation.
View Article and Find Full Text PDFIntroduction: Oesophageal cancer is associated with poor health outcomes. Upper GI (UGI) endoscopy is the gold standard for diagnosis but is associated with patient discomfort and low yield for cancer. We used a machine learning approach to create a model which predicted oesophageal cancer based on questionnaire responses.
View Article and Find Full Text PDFBackground And Aims: Long-term durability data for effectiveness of radiofrequency ablation (RFA) to prevent esophageal adenocarcinoma in patients with dysplastic Barrett's esophagus (BE) are lacking.
Methods: We prospectively collected data from 2535 patients with BE (mean length, 5.2 cm; range, 1-20) and neoplasia (20% low-grade dysplasia, 54% high-grade dysplasia, 26% intramucosal carcinoma) who underwent RFA therapy across 28 UK hospitals.
Article Synopsis
- Early detection of esophageal cancer (EAC) is important for improving survival rates, and researchers are working to find reliable markers to help with this.
- The study discovered 12 important gene-modules that change in EAC and found that these changes can also be seen in different patient groups, linking them to early signs of the disease.
- They also identified a special pattern in DNA from saliva that can indicate EAC, suggesting that testing saliva might help spot this cancer sooner and that two specific gene modules (CTNND2 and CCL20) should be studied more.
Oesophageal cancer is the sixth commonest cause of overall cancer mortality. Clinical staging utilizes multiple imaging modalities to guide treatment and prognostication. T2N0 oesophageal cancer is a treatment threshold for neoadjuvant therapy.
View Article and Find Full Text PDFObjective: The aim of this study was to determine the occurrence of latent tuberculosis infections (LTBI) and active TB in a cohort of patients with inflammatory bowel disease (IBD) treated with biologics. We also examined the effects of immunosuppressive drugs on indeterminate interferon-gamma release assays (IGRA) in LTBI screening.
Design: Retrospective study of patients treated with biologics between March 2007 and November 2015.